Abstract:Since the historical rediscovery of gastric spiral Helicobacter pylori in the gastric mucosa of patients with chronic gastritis by Warren and Marshall in 1983, peptic ulcer disease has been largely viewed as being of infectious aetiology. Indeed, there is a strong association between the presence of H. pylori and chronic active gastritis in histology. The bacterium can be isolated in not less than 70% of gastric and in over 90% of duodenal ulcer patients. Eradication of the organism has been associated with histologic improvement of gastritis, lower relapse rate and less risk of bleeding from duodenal ulcer. The bacterium possesses several virulence factors enabling it to survive the strong acid milieu inside the stomach and possibly damaging host tissues. The sequence of events by which the bacterium might cause gastric or duodenal ulcer is still not fully elucidated and Koch's postulates have never been fulfilled. In the majority of individuals, H. pylori infection is largely or entirely asymptomatic and there is no convincing data to suggest an increase in the prevalence of peptic ulcer disease among these subjects. An increasingly growing body of literature suggests an association between colonization by H. pylori in the stomach and a risk for developing gastric mucosa-associated lymphoid tissue (MALT), MALT lymphoma, gastric adenocarcinoma and even pancreatic adenocarcinoma. The bacterium has been implicated also in a number of extra-gastrointestinal disorders such as ischaemic heart disease, ischaemic cerebrovascular disease, atherosclerosis, and skin diseases such as rosacea, but a causal role for the bacterium is missing. Eradication of H. pylori thus seems to be a beneficial impact on human health. Various drug regimens are in use to eradicate H. pylori involving the administration of three or four drugs including bismuth compounds, metronidazole, clarithromycin, tetracyclines, amoxycillin, ranitidine, omeprazole for 1-2 weeks. The financial burden, side effects and emergence of drug resistant strains due to an increase in the use in antibiotics for H. pylori eradication therapy need further reconsideration.

1983–2023 – Vierzig Jahre Helicobacter pylori – und nun?

Helicobacter pylori Infection: A 40-Year Journey through Shifting the Paradigm to Transforming the Management

Helicobacter pylori: perspectives and time trends

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Helicobacter pylori Infection: New Facts in Clinical Management

[Helicobacter pylori -- 2010]

Review article: the global emergence of Helicobacter pylori antibiotic resistance

Helicobacter pylori infection: an overview in 2013, focus on therapy.

Diagnosis of Helicobacter pylori: Changes towards the Future

Current and Future Perspectives on the Management of Helicobacter pylori: A Narrative Review

Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies

A Century of Helicobacter pylori

Treatment of Helicobacter pylori infection 2016

The Changes of Main Upper Gastrointestinal Diseases and Helicobacter Pylori Infection Status in the Past Thirty Five Years

Helicobacter pylori. One bacterium and a broad spectrum of human disease! An overview

Treatment of Helicobacter pylori infection: Past, present and future

Updates to the Diagnosis and Clinical Management of Helicobacter pylori Infections

Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report

Review: Treatment of Helicobacter pylori Infection 2019

Review: Epidemiology of Helicobacter pylori infection

Helicobacter pylori: today's treatment, and possible future treatment